Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2026)

Catalyst Pharmaceuticals filings provide 4 years of Raw Materials readings, the most recent being $16.9 million for Q1 2026.

  • On a quarterly basis, Raw Materials rose 127.02% to $16.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.9 million, a 127.02% increase, with the full-year FY2025 number at $17.1 million, up 162.92% from a year prior.
  • Raw Materials hit $16.9 million in Q1 2026 for Catalyst Pharmaceuticals, down from $17.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $17.1 million in Q4 2025 to a low of $1.9 million in Q4 2023.
  • Median Raw Materials over the past 4 years was $6.9 million (2024), compared with a mean of $8.9 million.
  • Biggest five-year swings in Raw Materials: skyrocketed 241.26% in 2024 and later dropped 7.34% in 2025.
  • Catalyst Pharmaceuticals' Raw Materials stood at $1.9 million in 2023, then skyrocketed by 241.26% to $6.5 million in 2024, then soared by 162.92% to $17.1 million in 2025, then dropped by 1.51% to $16.9 million in 2026.
  • The last three reported values for Raw Materials were $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $12.1 million (Q3 2025) per Business Quant data.